What's in Pennington Biomedical Research Center's pipeline?

Pennington Biomedical Research Center has 3 drugs in our index: 3 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Pennington Biomedical Research Center's portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/pennington-biomedical-research-center.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Pennington Biomedical Research Center — Portfolio Competitive Intelligence Brief

Pennington Biomedical Research Center pipeline: 3 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Leptin A	Leptin A	marketed
Pioglitazone 45 mg	Pioglitazone 45 mg	marketed
sibutramine, orlistat, diethylpropion	sibutramine, orlistat, diethylpropion	marketed	Antiobesity agents (combination)	Norepinephrine transporter, serotonin transporter, pancreatic lipase, sympathomimetic amine receptor	Obesity / Weight Management

Therapeutic area mix

Obesity / Weight Management · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Pennington Biomedical Research Center:

Cite this brief

Drug Landscape (2026). Pennington Biomedical Research Center — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/pennington-biomedical-research-center. Accessed 2026-05-16.